GT BIOPHARMA, INC. Current Assets
GT BIOPHARMA, INC. (GTBP) had Current Assets of $5.79 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-14
- 2026-06-30: Assets, Current $5.79M.
- 2026-03-31: Assets, Current $10.00M.
- 2025-12-31: Assets, Current $8.11M.
- 2025-09-30: Assets, Current $4.32M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $5.79M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $8.11M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $4.32M 10-Q/A · filed 2026-03-06 |
| 2025-06-30 | $7.12M 10-Q/A · filed 2026-03-06 |
| 2025-03-31 | $2.66M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $4.23M 10-Q/A · filed 2026-03-06 |
| 2024-09-30 | $6.76M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $9.27M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $9.88M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $14.06M 10-K · filed 2025-02-21 |
| 2023-09-30 | $16.05M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $18.02M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $19.94M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $16.56M 10-K · filed 2024-03-26 |
| 2022-09-30 | $20.87M 10-Q · filed 2022-10-31 |
| 2022-06-30 | $23.95M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $27.19M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $32.17M 10-K · filed 2023-03-30 |
| 2021-09-30 | $35.80M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $39.57M 10-Q/A · filed 2021-12-29 |
| 2021-03-31 | $27.64M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $5.66M 10-K · filed 2022-03-28 |
| 2020-09-30 | $833.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $971.00K 10-Q/A · filed 2020-08-18 |
| 2020-03-31 | $188.00K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $274.00K 10-K · filed 2021-04-16 |
| 2019-09-30 | $337.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $286.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $78.00K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $90.00K 10-K · filed 2020-03-27 |
| 2018-09-30 | $1.25M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $1.10M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $2.87M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $576.00K 10-K · filed 2019-03-29 |
| 2017-09-30 | $2.73M 10-Q · filed 2017-11-14 |
| 2017-06-30 | $39.00K 10-Q · filed 2017-08-11 |
| 2017-03-31 | $235.00K 10-Q · filed 2017-04-28 |
| 2016-12-31 | $21.00K 10-K · filed 2018-03-01 |
| 2016-09-30 | $156.00K 10-Q/A · filed 2018-02-28 |
| 2016-06-30 | $357.00K 10-Q/A · filed 2018-02-28 |
| 2016-03-31 | $32.00K 10-Q/A · filed 2018-02-28 |
| 2015-12-31 | $49.00K 10-K/A · filed 2018-02-28 |
| 2015-09-30 | $44.00K 10-Q · filed 2015-11-13 |
| 2015-06-30 | $127.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | $1.42M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $882.00K 10-K/A · filed 2018-02-28 |
| 2014-09-30 | $690.00K 10-Q · filed 2015-01-08 |
| 2014-06-30 | $32.00K 10-Q · filed 2015-01-08 |
| 2014-03-31 | $77.00K 10-Q · filed 2015-01-08 |
| 2013-12-31 | $125.00K 10-K · filed 2015-03-31 |
| 2013-09-30 | $40.00K 10-Q · filed 2014-12-17 |
| 2013-06-30 | $131.00K 10-Q · filed 2014-12-12 |
| 2013-03-31 | $94.00K 10-Q · filed 2014-12-10 |
| 2012-12-31 | $202.00K 10-K · filed 2015-01-08 |
| 2012-09-30 | $73.00K 10-Q · filed 2012-11-21 |
| 2012-06-30 | $109.00K 10-Q/A · filed 2012-09-13 |
| 2012-03-31 | $144.00K 10-Q · filed 2012-05-21 |
| 2011-12-31 | $104.00K 10-K · filed 2014-11-18 |
| 2011-09-30 | $343.00K 10-Q · filed 2011-11-21 |
| 2011-06-30 | $194.00K 10-Q/A · filed 2011-09-12 |
| 2010-12-31 | $137.00K 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |